Welcome!

News Feed Item

Status Epilepticus Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Status Epilepticus Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280949/Status-Epilepticus-Global-Clinical-Trials-Review-H2-2014.html

Status Epilepticus Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Status Epilepticus Global Clinical Trials Review, H2, 2014" provides data on the Status Epilepticus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Status Epilepticus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Status Epilepticus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Status Epilepticus 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Status Epilepticus to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Status Epilepticus to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Status Epilepticus 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Status Epilepticus Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
Sage Therapeutics 30
Clinical Trial Overview of Sage Therapeutics 30
Ligand Pharmaceuticals, Inc. 31
Clinical Trial Overview of Ligand Pharmaceuticals, Inc. 31
Mylan Inc. 32
Clinical Trial Overview of Mylan Inc. 32
Clinical Trial Overview of Top Institutes / Government 33
Assistance Publique - Hopitaux de Paris 33
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 33
Eunice Kennedy Shriver National Institute of Child Health and Human Development 34
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 34
Xuanwu Hospital Capital Medical University 35
Clinical Trial Overview of Xuanwu Hospital Capital Medical University 35
University of Malawi 36
Clinical Trial Overview of University of Malawi 36
Postgraduate Institute of Medical Education and Research 37
Clinical Trial Overview of Postgraduate Institute of Medical Education and Research 37
Shiraz University of Medical Sciences 38
Clinical Trial Overview of Shiraz University of Medical Sciences 38
University of Virginia 39
Clinical Trial Overview of University of Virginia 39
Hillel Yaffe Medical Center 40
Clinical Trial Overview of Hillel Yaffe Medical Center 40
All India Institute of Medical Sciences 41
Clinical Trial Overview of All India Institute of Medical Sciences 41
University of Michigan 42
Clinical Trial Overview of University of Michigan 42
Five Key Clinical Profiles 43
Appendix 67
Abbreviations 67
Definitions 67
Research Methodology 68
Secondary Research 68
About GlobalData 69
Contact Us 69
Disclaimer 69
Source 69

List of Tables

Status Epilepticus Therapeutics, Global, Clinical Trials by Region, 2014* 7
Status Epilepticus Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Status Epilepticus Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Status Epilepticus Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Status Epilepticus Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Status Epilepticus Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Status Epilepticus Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Status Epilepticus Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Status Epilepticus Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Status Epilepticus Therapeutics, Global, Withdrawn Clinical Trials, 2014* 24
Status Epilepticus Therapeutics, Global, Terminated Clinical Trials, 2014* 24
Status Epilepticus Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Status Epilepticus Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 26
Status Epilepticus Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Status Epilepticus Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Status Epilepticus Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Sage Therapeutics, 2014* 30
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Ligand Pharmaceuticals, Inc., 2014* 31
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Mylan Inc., 2014* 32
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 33
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 34
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Xuanwu Hospital Capital Medical University, 2014* 35
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Malawi, 2014* 36
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Postgraduate Institute of Medical Education and Research, 2014* 37
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Shiraz University of Medical Sciences, 2014* 38
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Virginia, 2014* 39
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Hillel Yaffe Medical Center, 2014* 40
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by All India Institute of Medical Sciences, 2014* 41
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2014* 42

List of Figures

Status Epilepticus Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Status Epilepticus Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Status Epilepticus Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Status Epilepticus Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Status Epilepticus Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Status Epilepticus Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Status Epilepticus Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Status Epilepticus Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Status Epilepticus Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Status Epilepticus Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Status Epilepticus Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 26
Status Epilepticus Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Status Epilepticus Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Status Epilepticus Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
GlobalData Methodology 68


To order this report: Status Epilepticus Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280949/Status-Epilepticus-Global-Clinical-Trials-Review-H2-2014.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
As ridesharing competitors and enhanced services increase, notable changes are occurring in the transportation model. Despite the cost-effective means and flexibility of ridesharing, both drivers and users will need to be aware of the connected environment and how it will impact the ridesharing experience. In his session at @ThingsExpo, Timothy Evavold, Executive Director Automotive at Covisint, discussed key challenges and solutions to powering a ride sharing and/or multimodal model in the age ...
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. Commvault can ensure protection, access and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his general session at 18th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Part...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
"I will be talking about ChatOps and ChatOps as a way to solve some problems in the DevOps space," explained Himanshu Chhetri, CTO of Addteq, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Andi Mann, Chief Technology Advocate at Splunk, is an accomplished digital business executive with extensive global expertise as a strategist, technologist, innovator, marketer, and communicator. For over 30 years across five continents, he has built success with Fortune 500 corporations, vendors, governments, and as a leading research analyst and consultant.
In his session at @ThingsExpo, Dr. Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, presented the findings of a series of six detailed case studies of how large corporations are implementing IoT. The session explored how IoT has improved their economic performance, had major impacts on business models and resulted in impressive ROIs. The companies covered span manufacturing and services firms. He also explored servicification, how manufacturing firms shift from se...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settl...